Melanoma caught at its earliest stages is highly curable, with a five-year relative survival rate above 99% for localized disease that hasn’t spread beyond the skin. The realistic chance of a permanent cure drops as the stage advances, but even some patients with regional or distant spread now achieve long-term remissions thanks to newer treatments. Here’s what curability looks like at each stage.
Stage 0: Nearly 100% Curable
Stage 0, also called melanoma in situ, means abnormal cells are confined entirely to the top layer of skin (the epidermis). They haven’t invaded deeper tissue, so surgical removal is the only treatment needed. Most guidelines recommend cutting out the lesion with a margin of 5 to 10 millimeters of surrounding healthy skin, and the goal is to confirm that no abnormal cells remain at the edges. When those margins come back clear, the disease is considered cured. Follow-up typically involves an annual skin exam for life.
Stage I and II: High Cure Rates, Rising Risk
Stages I and II describe melanomas that remain localized to the skin with no evidence of spread to lymph nodes or distant organs. Together, these stages carry a five-year relative survival rate above 99% when measured as a group. But the picture gets more nuanced as tumor thickness increases.
What separates these substages is the depth of the tumor (measured in millimeters, called Breslow thickness) and whether the surface skin over the tumor is broken, or ulcerated. A thin Stage IA melanoma under 0.8 millimeters without ulceration is so low-risk that no further testing beyond surgery is typically recommended. Once a melanoma reaches 0.8 to 1.0 millimeters, or shows ulceration at a thinner depth, doctors will discuss a sentinel lymph node biopsy, a procedure that checks whether cancer cells have reached the nearest lymph node. For tumors thicker than 1.0 millimeter, that biopsy is strongly recommended.
The deeper substages carry meaningfully different recurrence risks. A large retrospective study at Memorial Sloan Kettering found five-year recurrence rates of about 22% for Stage IIA, 35% for Stage IIB, and 45% for Stage IIC. In fact, Stage IIC melanoma behaves more like Stage III disease in terms of recurrence patterns, with the highest risk concentrated in the first two to three years after diagnosis.
Because of this risk, the FDA approved an immunotherapy drug for patients with completely resected Stage IIB or IIC melanoma in December 2021. In clinical trials, patients who received up to a year of this post-surgery treatment had a 35% lower risk of recurrence compared to placebo. This represents a significant shift: patients who once would have simply been monitored after surgery now have an option to actively reduce their odds of the cancer coming back.
Stage III: Curable but Challenging
Stage III means melanoma has spread to nearby lymph nodes or developed satellite tumors in the surrounding skin, but hasn’t reached distant organs. This is where the word “curable” gets more complicated. A cure is still possible, especially with surgery and post-surgical immunotherapy, but recurrence rates are high.
Five-year recurrence rates climb steeply through the Stage III substages: roughly 48% for Stage IIIA, 71% for IIIB, and 85% for IIIC. The flip side of those numbers is that more than half of Stage IIIA patients remain recurrence-free at five years, and modern adjuvant therapy improves those odds further. In a five-year analysis published in NEJM Evidence, patients with Stage III melanoma who received immunotherapy after surgery had a recurrence-free survival rate of 55.4%, and about 60.6% remained free of distant spread. That means a meaningful proportion of Stage III patients are alive and cancer-free years later.
When recurrence does happen at this stage, it tends to come early. The average time to recurrence for Stage III is roughly 12 to 14 months, and the majority of recurrences happen within three years. This is why follow-up appointments are frequent: every three to six months for the first two years, then gradually tapering over the next several years.
Stage IV: Rarely Cured, but Outcomes Are Improving
Stage IV melanoma has spread to distant organs such as the lungs, liver, brain, or distant lymph nodes. Historically, this stage carried a median survival measured in months, with five-year survival in the single digits. The introduction of immunotherapy and targeted therapy has changed the landscape dramatically. A subset of patients, estimated at roughly 20 to 30% in major clinical trials, now achieve durable responses lasting five years or more. Some oncologists use the word “functional cure” for these patients, meaning the cancer is controlled long enough that it may never return, though certainty is difficult.
The five-year relative survival rate for distant melanoma has improved but remains far lower than for earlier stages. Complete, permanent cures at Stage IV do occur, but they are the exception rather than the rule. Treatment response depends on factors like where the cancer has spread, tumor genetics, and how the immune system responds to therapy.
What Determines Curability Beyond Stage
Stage is the single biggest predictor of cure, but several other factors matter. Tumor thickness is the most important characteristic of the primary melanoma. Ulceration of the tumor surface independently worsens prognosis at every stage. A positive sentinel lymph node biopsy can upstage a seemingly localized melanoma to Stage III. And the rate at which cells are dividing within the tumor, along with whether the cancer carries certain genetic mutations, can influence both prognosis and treatment options.
The location of the melanoma also plays a role in follow-up strategy. Patients with thicker tumors or higher-stage disease are monitored more aggressively. German and Swiss guidelines recommend lymph node ultrasounds every three to six months for the first five years in Stage III patients, while patients with thin Stage I melanomas may only need exams every six to twelve months. Most guidelines agree on one thing: skin surveillance should continue for life, because people who’ve had one melanoma are at increased risk of developing another.
Recurrence Timelines by Stage
Understanding when recurrence is most likely can help frame what follow-up looks like in practical terms. For Stage I melanoma, 80% of recurrences happen within the first three years, with a mean time to recurrence around 34 to 40 months. Stage II recurrences cluster earlier, with a mean around 18 to 22 months. Stage III recurrences come fastest, averaging 12 to 14 months.
Studies pooling Stage I and II patients together found a one-year recurrence rate of about 9% and a ten-year rate of roughly 23%. The risk never fully reaches zero, which is why long-term follow-up matters even for early-stage patients. But the further you get from diagnosis without recurrence, the lower your ongoing risk becomes. After five recurrence-free years, many guidelines shift to annual check-ups, reflecting the substantially reduced (though not eliminated) likelihood of late recurrence.